JPRN-UMIN000015997招募中未知
WT1 peptide-based cancer vaccine for long-term maintenance of anti-tumor immunity - WT1 vaccine for long-term anti-tumor immunity
Osaka University Graduate Shool of Medicine, Functional Diagnostic Science0 个研究点目标入组 56 人开始时间: 2014年12月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. having severe infectious disease 2. having developed adverse effects (grade >=4) in the prior WT1 peptide vaccine trial 3. having severe complications 4. having severe mental disorders
研究者
相似试验
已完成
2 期
WT1 peptide-based cancer vaccine combined with gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a randomised, multicenter, phase 2 clinical studyPancreatic cancerJPRN-UMIN000005248Department of Cancer Immunotherapy, Osaka university Graduate school of Medicine150
尚未招募
2 期
WT1 peptide-based cancer vaccine in patients with high risk rhabdomyosarcoma, a multicenter, phase 2 clinical studyrhabdomyosarcomaJPRN-UMIN000013325Osaka university graduate school of medicine Pediatrics33
招募中
不适用
WT1 Trio Peptide-vaccine for Rare CancersJPRN-UMIN000023579Osaka University Graduate School of Medicine Dept. Cancer Immunotherapy90
已完成
1 期
Cancer Vaccine Therapy using Epitope Peptide Restricted to HLA-A*02 (URLC10) in Patients with Non-small Cell Lung Cancer Refractory to Standard Therapy (Phase I study)on-small Cell Lung CancerJPRN-UMIN000003190Shiga University of Medical Science9
已完成
1 期
Cancer Vaccine Therapy using Epitope Peptide Restricted to HLA-A*24 (CDCA1,KIF20A) in Patients with Small Cell Lung Cancer Refractory to Standard Therapy (Phase I study).Small Cell Lung CancerJPRN-UMIN000003191Shiga University of Medical Science9